Navigation Links
C8 Science Panel Completes Uric Acid Study

PARKERSBURG, W. Va., Jan. 27 /PRNewswire/ -- The C8 Science Panel has completed a new study on uric acid and C8 and C8S, based on existing data from the C8 Health Project. While increased uric acid is associated with higher levels of C8 and C8S, the data are not sufficient to show that these chemicals can cause an increase in uric acid.

The Science Panel team recently completed a study on the relationship between uric acid and C8 (also known as PFOA) and C8S (also known as PFOS) in the blood among Mid-Ohio Valley residents who participated in the C8 Health Project in 2005-2006. This study was done in collaboration with researchers at West Virginia University. A summary of the results of this study has now been filed with the court in Wood County, West Virginia, as required under a court settlement of a class action suit in 2004, and will be available at the C8 Science Panel website,

Uric acid is a natural component of the blood, coming largely from dietary sources, particularly meat. Very high levels of uric acid can lead to gout, a form of arthritis, and high uric acid has been associated with higher blood pressure in epidemiologic studies. C8 is present at relatively high levels among many Mid-Ohio Valley residents due to drinking water contaminated with C8 coming from the local DuPont chemical plant. DuPont did not release C8S from the plant, and C8S levels in Mid-Ohio Valley residents are similar to levels in the general US population.

The C8 Science Panel found that that higher serum levels of both C8 and C8S were each independently and significantly associated with a higher uric acid in the blood of 55,000 adults who participated in the C8 Health Project in 2005-2006. However, because of the fact that uric acid and C8/C8S were measured at the same time, they could not determine if an increase in either C8 or C8S would cause an increase in uric acid. Other possibilities include that both uric acid and these two chemicals increase in relation to some other unknown chemical in the blood, or even that an increase in uric acid in fact causes increased retention and blood levels of C8 and C8S for unknown reasons. Because of this lack of knowledge about which came first, the uric acid increase or the C8/C8S increase, no firm conclusions about a causal relationship between C8 and C8S and uric acid can be drawn from these findings.

The C8 Science Panel was chosen to determine whether a probable link exists between C8 and human disease as part of a class action settlement of a lawsuit involving releases of a chemical known as C8 from DuPont's Washington Works in Wood County, West Virginia. The C8 Science Panel is made up of three scientists from universities in London, Atlanta and New York. The three panelists were agreed upon by both DuPont and the plaintiffs. They are Dr. Tony Fletcher, Dr. Kyle Steenland, and Dr. David Savitz. More information as well as a schedule of studies can be found at

SOURCE The C8 Science Panel
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. This February Discovery en Espanol Delves Into The Subconscious World of Attraction in Science of Sex Appeal
2. Light Sciences Oncology Elects Former FDA Commissioner Frank Young, M.D., Ph.D., to Board of Directors
3. American Heart Association Science Advisory - Omega-6 Fatty Acids: Make Them a Part of Heart-Healthy Eating
4. SpectraScience Announces Business Update
5. Elsevier to launch over 600 health science e-Book titles on ScienceDirect
6. Elsevier to Launch Over 600 Health Science E-Book Titles on ScienceDirect
7. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
8. American Heart Association 2008 Wrap-Up Report: Top Research Advances Include Studies That Influence Medical Care, Apply Science To Real World Communities
9. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
10. BioMed Realty Trusts Center for Life Science Boston Now 91% Leased
11. Bishops Urge New President to Keep Laws on Conscience Rights, Foreign Aid for Abortion, Embryonic Stem Cell Research
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: